Zealand Pharma announced that the FDA has accepted for filing the company’s New Drug Application (NDA) for the HypoPal Rescue Pen (dasiglucagon) for the treatment of hypoglycemia in people with diabetes.
Sanofi announced new evidence from a real-world observational study demonstrating significantly less risk of documented hypoglycemia with similar blood sugar...
Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for dasiglucagon injection for the treatment of severe hypoglycemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus
Merck has announced results from a post-hoc analysis of Phase III data showing that patients with Type 2 Diabetes having...
Medtronic plc announced results of a retrospective analysis based on real-world data from over 20,000 MiniMed� 530G users, which found...
Zealand Pharma announced that the FDA has approved Zegalogue (dasiglucagon) injection for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.The FDA approval was based on efficacy results from three randomized, double-blind, placebo-controlled multicenter Phase III studies of Zegalogue in children aged 6 to 17 and in adults with type 1 diabetes.
Zealand Pharma announced it has achieved primary and key secondary endpoints in the pivotal Phase III trial with ZP 4207...
Zealand Pharma A/S announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize Zegalogue (dasiglucagon) for injection
Xeris Pharmaceuticals, Inc. announced that it has received regulatory approval from the FDA for Gvoke (glucagon) injection, its ready-to-use, room-temperature...
Zealand Pharma announced that the primary and key secondary objectives of the first multinational Phase III clinical trial of ZP...